Sinclair to Announce New Global Brand Transformation at IMCAS 2022Sinclair to Announce New Global Brand Transformation at IMCAS 2022

Sinclair to Announce New Global Brand Transformation at IMCAS 2022

Sinclair, (www.sinclair.com) a global aesthetics company headquartered in London and fully owned subsidiary of Huadong Medicine Corporation Limited announces the launch of a major rebranding.


Sinclair has been on an ambitious journey over the past 3 years and has grown significantly since Huadong Medicine acquired the company in 2018. An already unique portfolio of minimally invasive injectables has been enhanced by the acquisition of carefully selected complementary products. MaiLi brings the latest and most advanced HA technology to the market. Lanluma allows clinicians to use a collagen stimulating injectable in face and body and our new EBD division adds an entire suite of next generation energy-based technologies. The new brand reflects this ever-expanding portfolio, the development of educational programmes through Sinclair College, and a growing global presence.


The brand has been transformed to be modern, vibrant and premium, balancing elegance and dynamism.


The new branding is also designed to reflect company values: Agility, Ambition and Entrepreneurship. With a constant evolution of the business, understanding the needs of clinicians and their customers is a constant driving force. The company strives to be the best at what it does, driving product development, team dynamics and ultimately success. Honesty, passion, determination and confidence are all qualities that define Sinclair. It’s this spirit that keeps the organisation moving in the right direction.


Working closely with the Manchester based creative agency Truth Creative, Sinclair’s global marketing team have created a new brand that reflects these values and will facilitate continued success long into the future.

Emilie Croissant, head of Sinclair global marketing commented, “There's a traditional belief that updating a brand is just updating the logo and colours, that's part of it but it's more than that. It's about transforming customer confidence and letting customers know we are by their side through all our global communication. We needed to engage our global teams with the same brand vision. This foundation allowed us to develop the brand identity to match our global ambition and cement our place as a serious worldwide aesthetics brand.”


Jo Scott, founder of Truth Creative said, “Sinclair is an ambitious global company which wants to continue growing its product range and reach in a competitive market. Building on Truth Creative’s extensive experience in the global healthcare aesthetics sector, we have provided Sinclair with an updated brand identity which matches its future goals.”


To see the new brand and see the transformation of the Sinclair training platform visit www.sinclair.com; https://www.linkedin.com/company/sinclair-pharmaceuticals-ltd; and on Instagram @sinclair.global

About Huadong Medicine Co., Ltd.


HMC(SZ.000963), listed in 1999, is one of the top manufacturers and distributors of pharmaceutical and medical products in China, where it has over 12,000 employees and generated approximately $5.1 billion of revenue in the financial year ended 31 December 2021. Over the past five years, HMC has established a leading aesthetics business in China, offering a variety of fillers. HMC is an affiliate of China Grand Enterprise Inc. (CGE), an investment group headquartered in Beijing. CGE has four business sectors: pharmaceuticals and healthcare, commodities trading, real estate investment and financial services, among which, pharmaceuticals and healthcare sector is the core business. CGE is ranked in the top five enterprises in the Chinese Pharmaceutical industry and manages over 60 pharmaceutical subsidiary companies, HMC is the largest one.

About Sinclair


Sinclair is an international company operating in the fast growth, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies in both the injectable and EBD segments. Both divisions are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the EU markets, Brazil, Mexico, Colombia, UAE, Hong Kong and South Korea and a network of international distributors.


For more information, visit www.sinclair.com

Media Contacts:


Emilie Croissant, Lee Anne Evans, Dave Baldwin
Email: info@sinclair.com
Tel: +44 (0) 20 7467 6920

Instagram

Sinclair Global